Global Cell and Gene Therapy CDMO Supply, Demand and Key Producers, 2026-2032
The global Cell and Gene Therapy CDMO market size is expected to reach $ 6608 million by 2032, rising at a market growth of 6.7% CAGR during the forecast period (2026-2032).
Cell and Gene Therapy CDMOs are organizations that provide professional, customized R&D and manufacturing outsourcing services for the research and commercialization of cell and gene therapy drugs. These services cover the entire chain of process development and manufacturing, from plasmids and viral vectors to cell drugs. Their core value lies in helping innovative cell and gene therapy (CGT) companies overcome industrialization bottlenecks caused by complex processes, high production costs, and stringent regulatory oversight, accelerating the drug development process from preclinical research to IND application and commercialization. Services include process development, analytical method development, GMP-level manufacturing, stability studies, and application document preparation, making them an indispensable key support force in modern CGT drug development.
The global Cell and Gene Therapy CDMO market is experiencing rapid growth driven by the surge in CGT drugs, pipeline advancements, and industrialization demands. North America and Europe, as mature markets, leverage their leading viral vector technologies, robust regulatory frameworks, and extensive CGT R&D pipelines to hold leading positions in AAV suspension processes, lentiviral GMP production, and plasmid CDMO. The Asia-Pacific region has become the fastest-growing and most rapidly expanding sector. China, with its leading global number of cell therapy clinical studies, policy support, and CXO industry chain advantages, is driving the rapid rise of autologous CAR-T CDMO, universal cell therapy, and viral vector outsourcing services, with domestic CDMOs quickly entering global competition. The industry as a whole is accelerating its evolution towards suspension process scale-up, gene editing integration, and automated closed-loop production.
This report studies the global Cell and Gene Therapy CDMO demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cell and Gene Therapy CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cell and Gene Therapy CDMO that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cell and Gene Therapy CDMO total market, 2021-2032, (USD Million)
Global Cell and Gene Therapy CDMO total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cell and Gene Therapy CDMO total market, key domestic companies, and share, (USD Million)
Global Cell and Gene Therapy CDMO revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cell and Gene Therapy CDMO total market by Type, CAGR, 2021-2032, (USD Million)
Global Cell and Gene Therapy CDMO total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cell and Gene Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, Made Scientific, RoslinCT, Thermo Scientific, Andelyn Biosciences, WuXi AppTec, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cell and Gene Therapy CDMO market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cell and Gene Therapy CDMO Market, By Region:
1. How big is the global Cell and Gene Therapy CDMO market?
2. What is the demand of the global Cell and Gene Therapy CDMO market?
3. What is the year over year growth of the global Cell and Gene Therapy CDMO market?
4. What is the total value of the global Cell and Gene Therapy CDMO market?
5. Who are the Major Players in the global Cell and Gene Therapy CDMO market?
6. What are the growth factors driving the market demand?
Cell and Gene Therapy CDMOs are organizations that provide professional, customized R&D and manufacturing outsourcing services for the research and commercialization of cell and gene therapy drugs. These services cover the entire chain of process development and manufacturing, from plasmids and viral vectors to cell drugs. Their core value lies in helping innovative cell and gene therapy (CGT) companies overcome industrialization bottlenecks caused by complex processes, high production costs, and stringent regulatory oversight, accelerating the drug development process from preclinical research to IND application and commercialization. Services include process development, analytical method development, GMP-level manufacturing, stability studies, and application document preparation, making them an indispensable key support force in modern CGT drug development.
The global Cell and Gene Therapy CDMO market is experiencing rapid growth driven by the surge in CGT drugs, pipeline advancements, and industrialization demands. North America and Europe, as mature markets, leverage their leading viral vector technologies, robust regulatory frameworks, and extensive CGT R&D pipelines to hold leading positions in AAV suspension processes, lentiviral GMP production, and plasmid CDMO. The Asia-Pacific region has become the fastest-growing and most rapidly expanding sector. China, with its leading global number of cell therapy clinical studies, policy support, and CXO industry chain advantages, is driving the rapid rise of autologous CAR-T CDMO, universal cell therapy, and viral vector outsourcing services, with domestic CDMOs quickly entering global competition. The industry as a whole is accelerating its evolution towards suspension process scale-up, gene editing integration, and automated closed-loop production.
This report studies the global Cell and Gene Therapy CDMO demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cell and Gene Therapy CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cell and Gene Therapy CDMO that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cell and Gene Therapy CDMO total market, 2021-2032, (USD Million)
Global Cell and Gene Therapy CDMO total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Cell and Gene Therapy CDMO total market, key domestic companies, and share, (USD Million)
Global Cell and Gene Therapy CDMO revenue by player, revenue and market share 2021-2026, (USD Million)
Global Cell and Gene Therapy CDMO total market by Type, CAGR, 2021-2032, (USD Million)
Global Cell and Gene Therapy CDMO total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Cell and Gene Therapy CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, Made Scientific, RoslinCT, Thermo Scientific, Andelyn Biosciences, WuXi AppTec, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Cell and Gene Therapy CDMO market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Cell and Gene Therapy CDMO Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Clinical Trial Material CDMOs
- Development and Manufacturing CDMOs
- Other
- R&D-Grade CDMO
- Clinical-Grade CDMO
- Commercial-Scale CDMO
- Plasmid DNA CDMO
- Viral Vector CDMO
- Cell Therapy CDMO
- mRNA Drug CDMO
- Gene Editing Drug CDMO
- Others
- Pharmaceutical Company
- Biotechnology Company
- Other
- Lonza
- Charles River Laboratories
- Cytiva
- Catalent Biologics
- FUJIFILM Diosynth Biotechnologies
- Made Scientific
- RoslinCT
- Thermo Scientific
- Andelyn Biosciences
- WuXi AppTec
- AGC Biologics
- Pfizer CentreOne
- Almac Group
- PCI Pharma Services
- OmniaBio
- Minaris Advanced Therapies
1. How big is the global Cell and Gene Therapy CDMO market?
2. What is the demand of the global Cell and Gene Therapy CDMO market?
3. What is the year over year growth of the global Cell and Gene Therapy CDMO market?
4. What is the total value of the global Cell and Gene Therapy CDMO market?
5. Who are the Major Players in the global Cell and Gene Therapy CDMO market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Cell and Gene Therapy CDMO Introduction
1.2 World Cell and Gene Therapy CDMO Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cell and Gene Therapy CDMO Total Market by Region (by Headquarter Location)
1.3.1 World Cell and Gene Therapy CDMO Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.3 China Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.4 Europe Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.5 Japan Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.6 South Korea Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.7 ASEAN Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.8 India Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cell and Gene Therapy CDMO Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.2 World Cell and Gene Therapy CDMO Consumption Value by Region
2.2.1 World Cell and Gene Therapy CDMO Consumption Value by Region (2021-2026)
2.2.2 World Cell and Gene Therapy CDMO Consumption Value Forecast by Region (2027-2032)
2.3 United States Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.4 China Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.5 Europe Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.6 Japan Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.7 South Korea Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.8 ASEAN Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.9 India Cell and Gene Therapy CDMO Consumption Value (2021-2032)
3 WORLD CELL AND GENE THERAPY CDMO COMPANIES COMPETITIVE ANALYSIS
3.1 World Cell and Gene Therapy CDMO Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cell and Gene Therapy CDMO Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cell and Gene Therapy CDMO in 2025
3.2.3 Global Concentration Ratios (CR8) for Cell and Gene Therapy CDMO in 2025
3.3 Cell and Gene Therapy CDMO Company Evaluation Quadrant
3.4 Cell and Gene Therapy CDMO Market: Overall Company Footprint Analysis
3.4.1 Cell and Gene Therapy CDMO Market: Region Footprint
3.4.2 Cell and Gene Therapy CDMO Market: Company Product Type Footprint
3.4.3 Cell and Gene Therapy CDMO Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cell and Gene Therapy CDMO Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cell and Gene Therapy CDMO Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cell and Gene Therapy CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cell and Gene Therapy CDMO Consumption Value Comparison
4.2.1 United States VS China: Cell and Gene Therapy CDMO Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cell and Gene Therapy CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cell and Gene Therapy CDMO Companies and Market Share, 2021-2026
4.3.1 United States Based Cell and Gene Therapy CDMO Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026)
4.4 China Based Companies Cell and Gene Therapy CDMO Revenue and Market Share, 2021-2026
4.4.1 China Based Cell and Gene Therapy CDMO Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026)
4.5 Rest of World Based Cell and Gene Therapy CDMO Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cell and Gene Therapy CDMO Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cell and Gene Therapy CDMO Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Clinical Trial Material CDMOs
5.2.2 Development and Manufacturing CDMOs
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Cell and Gene Therapy CDMO Market Size by Type (2021-2026)
5.3.2 World Cell and Gene Therapy CDMO Market Size by Type (2027-2032)
5.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SCALE
6.1 World Cell and Gene Therapy CDMO Market Size Overview by Scale: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Scale
6.2.1 R&D-Grade CDMO
6.2.2 Clinical-Grade CDMO
6.2.3 Commercial-Scale CDMO
6.3 Market Segment by Scale
6.3.1 World Cell and Gene Therapy CDMO Market Size by Scale (2021-2026)
6.3.2 World Cell and Gene Therapy CDMO Market Size by Scale (2027-2032)
6.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Scale (2027-2032)
7 MARKET ANALYSIS BY TECHNOLOGY
7.1 World Cell and Gene Therapy CDMO Market Size Overview by Technology: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Technology
7.2.1 Plasmid DNA CDMO
7.2.2 Viral Vector CDMO
7.2.3 Cell Therapy CDMO
7.2.4 mRNA Drug CDMO
7.2.5 Gene Editing Drug CDMO
7.2.6 Others
7.3 Market Segment by Technology
7.3.1 World Cell and Gene Therapy CDMO Market Size by Technology (2021-2026)
7.3.2 World Cell and Gene Therapy CDMO Market Size by Technology (2027-2032)
7.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Technology (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cell and Gene Therapy CDMO Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical Company
8.2.2 Biotechnology Company
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Cell and Gene Therapy CDMO Market Size by Application (2021-2026)
8.3.2 World Cell and Gene Therapy CDMO Market Size by Application (2027-2032)
8.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Lonza
9.1.1 Lonza Details
9.1.2 Lonza Major Business
9.1.3 Lonza Cell and Gene Therapy CDMO Product and Services
9.1.4 Lonza Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Lonza Recent Developments/Updates
9.1.6 Lonza Competitive Strengths & Weaknesses
9.2 Charles River Laboratories
9.2.1 Charles River Laboratories Details
9.2.2 Charles River Laboratories Major Business
9.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Product and Services
9.2.4 Charles River Laboratories Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Charles River Laboratories Recent Developments/Updates
9.2.6 Charles River Laboratories Competitive Strengths & Weaknesses
9.3 Cytiva
9.3.1 Cytiva Details
9.3.2 Cytiva Major Business
9.3.3 Cytiva Cell and Gene Therapy CDMO Product and Services
9.3.4 Cytiva Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Cytiva Recent Developments/Updates
9.3.6 Cytiva Competitive Strengths & Weaknesses
9.4 Catalent Biologics
9.4.1 Catalent Biologics Details
9.4.2 Catalent Biologics Major Business
9.4.3 Catalent Biologics Cell and Gene Therapy CDMO Product and Services
9.4.4 Catalent Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Catalent Biologics Recent Developments/Updates
9.4.6 Catalent Biologics Competitive Strengths & Weaknesses
9.5 FUJIFILM Diosynth Biotechnologies
9.5.1 FUJIFILM Diosynth Biotechnologies Details
9.5.2 FUJIFILM Diosynth Biotechnologies Major Business
9.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product and Services
9.5.4 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
9.5.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
9.6 Made Scientific
9.6.1 Made Scientific Details
9.6.2 Made Scientific Major Business
9.6.3 Made Scientific Cell and Gene Therapy CDMO Product and Services
9.6.4 Made Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Made Scientific Recent Developments/Updates
9.6.6 Made Scientific Competitive Strengths & Weaknesses
9.7 RoslinCT
9.7.1 RoslinCT Details
9.7.2 RoslinCT Major Business
9.7.3 RoslinCT Cell and Gene Therapy CDMO Product and Services
9.7.4 RoslinCT Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 RoslinCT Recent Developments/Updates
9.7.6 RoslinCT Competitive Strengths & Weaknesses
9.8 Thermo Scientific
9.8.1 Thermo Scientific Details
9.8.2 Thermo Scientific Major Business
9.8.3 Thermo Scientific Cell and Gene Therapy CDMO Product and Services
9.8.4 Thermo Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Thermo Scientific Recent Developments/Updates
9.8.6 Thermo Scientific Competitive Strengths & Weaknesses
9.9 Andelyn Biosciences
9.9.1 Andelyn Biosciences Details
9.9.2 Andelyn Biosciences Major Business
9.9.3 Andelyn Biosciences Cell and Gene Therapy CDMO Product and Services
9.9.4 Andelyn Biosciences Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Andelyn Biosciences Recent Developments/Updates
9.9.6 Andelyn Biosciences Competitive Strengths & Weaknesses
9.10 WuXi AppTec
9.10.1 WuXi AppTec Details
9.10.2 WuXi AppTec Major Business
9.10.3 WuXi AppTec Cell and Gene Therapy CDMO Product and Services
9.10.4 WuXi AppTec Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 WuXi AppTec Recent Developments/Updates
9.10.6 WuXi AppTec Competitive Strengths & Weaknesses
9.11 AGC Biologics
9.11.1 AGC Biologics Details
9.11.2 AGC Biologics Major Business
9.11.3 AGC Biologics Cell and Gene Therapy CDMO Product and Services
9.11.4 AGC Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 AGC Biologics Recent Developments/Updates
9.11.6 AGC Biologics Competitive Strengths & Weaknesses
9.12 Pfizer CentreOne
9.12.1 Pfizer CentreOne Details
9.12.2 Pfizer CentreOne Major Business
9.12.3 Pfizer CentreOne Cell and Gene Therapy CDMO Product and Services
9.12.4 Pfizer CentreOne Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Pfizer CentreOne Recent Developments/Updates
9.12.6 Pfizer CentreOne Competitive Strengths & Weaknesses
9.13 Almac Group
9.13.1 Almac Group Details
9.13.2 Almac Group Major Business
9.13.3 Almac Group Cell and Gene Therapy CDMO Product and Services
9.13.4 Almac Group Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Almac Group Recent Developments/Updates
9.13.6 Almac Group Competitive Strengths & Weaknesses
9.14 PCI Pharma Services
9.14.1 PCI Pharma Services Details
9.14.2 PCI Pharma Services Major Business
9.14.3 PCI Pharma Services Cell and Gene Therapy CDMO Product and Services
9.14.4 PCI Pharma Services Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 PCI Pharma Services Recent Developments/Updates
9.14.6 PCI Pharma Services Competitive Strengths & Weaknesses
9.15 OmniaBio
9.15.1 OmniaBio Details
9.15.2 OmniaBio Major Business
9.15.3 OmniaBio Cell and Gene Therapy CDMO Product and Services
9.15.4 OmniaBio Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 OmniaBio Recent Developments/Updates
9.15.6 OmniaBio Competitive Strengths & Weaknesses
9.16 Minaris Advanced Therapies
9.16.1 Minaris Advanced Therapies Details
9.16.2 Minaris Advanced Therapies Major Business
9.16.3 Minaris Advanced Therapies Cell and Gene Therapy CDMO Product and Services
9.16.4 Minaris Advanced Therapies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Minaris Advanced Therapies Recent Developments/Updates
9.16.6 Minaris Advanced Therapies Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cell and Gene Therapy CDMO Industry Chain
10.2 Cell and Gene Therapy CDMO Upstream Analysis
10.3 Cell and Gene Therapy CDMO Midstream Analysis
10.4 Cell and Gene Therapy CDMO Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Cell and Gene Therapy CDMO Introduction
1.2 World Cell and Gene Therapy CDMO Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Cell and Gene Therapy CDMO Total Market by Region (by Headquarter Location)
1.3.1 World Cell and Gene Therapy CDMO Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.3 China Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.4 Europe Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.5 Japan Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.6 South Korea Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.7 ASEAN Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.3.8 India Based Company Cell and Gene Therapy CDMO Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cell and Gene Therapy CDMO Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.2 World Cell and Gene Therapy CDMO Consumption Value by Region
2.2.1 World Cell and Gene Therapy CDMO Consumption Value by Region (2021-2026)
2.2.2 World Cell and Gene Therapy CDMO Consumption Value Forecast by Region (2027-2032)
2.3 United States Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.4 China Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.5 Europe Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.6 Japan Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.7 South Korea Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.8 ASEAN Cell and Gene Therapy CDMO Consumption Value (2021-2032)
2.9 India Cell and Gene Therapy CDMO Consumption Value (2021-2032)
3 WORLD CELL AND GENE THERAPY CDMO COMPANIES COMPETITIVE ANALYSIS
3.1 World Cell and Gene Therapy CDMO Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Cell and Gene Therapy CDMO Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Cell and Gene Therapy CDMO in 2025
3.2.3 Global Concentration Ratios (CR8) for Cell and Gene Therapy CDMO in 2025
3.3 Cell and Gene Therapy CDMO Company Evaluation Quadrant
3.4 Cell and Gene Therapy CDMO Market: Overall Company Footprint Analysis
3.4.1 Cell and Gene Therapy CDMO Market: Region Footprint
3.4.2 Cell and Gene Therapy CDMO Market: Company Product Type Footprint
3.4.3 Cell and Gene Therapy CDMO Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Cell and Gene Therapy CDMO Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Cell and Gene Therapy CDMO Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Cell and Gene Therapy CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Cell and Gene Therapy CDMO Consumption Value Comparison
4.2.1 United States VS China: Cell and Gene Therapy CDMO Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Cell and Gene Therapy CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Cell and Gene Therapy CDMO Companies and Market Share, 2021-2026
4.3.1 United States Based Cell and Gene Therapy CDMO Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026)
4.4 China Based Companies Cell and Gene Therapy CDMO Revenue and Market Share, 2021-2026
4.4.1 China Based Cell and Gene Therapy CDMO Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026)
4.5 Rest of World Based Cell and Gene Therapy CDMO Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Cell and Gene Therapy CDMO Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Cell and Gene Therapy CDMO Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Clinical Trial Material CDMOs
5.2.2 Development and Manufacturing CDMOs
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Cell and Gene Therapy CDMO Market Size by Type (2021-2026)
5.3.2 World Cell and Gene Therapy CDMO Market Size by Type (2027-2032)
5.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SCALE
6.1 World Cell and Gene Therapy CDMO Market Size Overview by Scale: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Scale
6.2.1 R&D-Grade CDMO
6.2.2 Clinical-Grade CDMO
6.2.3 Commercial-Scale CDMO
6.3 Market Segment by Scale
6.3.1 World Cell and Gene Therapy CDMO Market Size by Scale (2021-2026)
6.3.2 World Cell and Gene Therapy CDMO Market Size by Scale (2027-2032)
6.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Scale (2027-2032)
7 MARKET ANALYSIS BY TECHNOLOGY
7.1 World Cell and Gene Therapy CDMO Market Size Overview by Technology: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Technology
7.2.1 Plasmid DNA CDMO
7.2.2 Viral Vector CDMO
7.2.3 Cell Therapy CDMO
7.2.4 mRNA Drug CDMO
7.2.5 Gene Editing Drug CDMO
7.2.6 Others
7.3 Market Segment by Technology
7.3.1 World Cell and Gene Therapy CDMO Market Size by Technology (2021-2026)
7.3.2 World Cell and Gene Therapy CDMO Market Size by Technology (2027-2032)
7.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Technology (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Cell and Gene Therapy CDMO Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Pharmaceutical Company
8.2.2 Biotechnology Company
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Cell and Gene Therapy CDMO Market Size by Application (2021-2026)
8.3.2 World Cell and Gene Therapy CDMO Market Size by Application (2027-2032)
8.3.3 World Cell and Gene Therapy CDMO Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Lonza
9.1.1 Lonza Details
9.1.2 Lonza Major Business
9.1.3 Lonza Cell and Gene Therapy CDMO Product and Services
9.1.4 Lonza Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Lonza Recent Developments/Updates
9.1.6 Lonza Competitive Strengths & Weaknesses
9.2 Charles River Laboratories
9.2.1 Charles River Laboratories Details
9.2.2 Charles River Laboratories Major Business
9.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Product and Services
9.2.4 Charles River Laboratories Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Charles River Laboratories Recent Developments/Updates
9.2.6 Charles River Laboratories Competitive Strengths & Weaknesses
9.3 Cytiva
9.3.1 Cytiva Details
9.3.2 Cytiva Major Business
9.3.3 Cytiva Cell and Gene Therapy CDMO Product and Services
9.3.4 Cytiva Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Cytiva Recent Developments/Updates
9.3.6 Cytiva Competitive Strengths & Weaknesses
9.4 Catalent Biologics
9.4.1 Catalent Biologics Details
9.4.2 Catalent Biologics Major Business
9.4.3 Catalent Biologics Cell and Gene Therapy CDMO Product and Services
9.4.4 Catalent Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Catalent Biologics Recent Developments/Updates
9.4.6 Catalent Biologics Competitive Strengths & Weaknesses
9.5 FUJIFILM Diosynth Biotechnologies
9.5.1 FUJIFILM Diosynth Biotechnologies Details
9.5.2 FUJIFILM Diosynth Biotechnologies Major Business
9.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product and Services
9.5.4 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
9.5.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
9.6 Made Scientific
9.6.1 Made Scientific Details
9.6.2 Made Scientific Major Business
9.6.3 Made Scientific Cell and Gene Therapy CDMO Product and Services
9.6.4 Made Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Made Scientific Recent Developments/Updates
9.6.6 Made Scientific Competitive Strengths & Weaknesses
9.7 RoslinCT
9.7.1 RoslinCT Details
9.7.2 RoslinCT Major Business
9.7.3 RoslinCT Cell and Gene Therapy CDMO Product and Services
9.7.4 RoslinCT Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 RoslinCT Recent Developments/Updates
9.7.6 RoslinCT Competitive Strengths & Weaknesses
9.8 Thermo Scientific
9.8.1 Thermo Scientific Details
9.8.2 Thermo Scientific Major Business
9.8.3 Thermo Scientific Cell and Gene Therapy CDMO Product and Services
9.8.4 Thermo Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Thermo Scientific Recent Developments/Updates
9.8.6 Thermo Scientific Competitive Strengths & Weaknesses
9.9 Andelyn Biosciences
9.9.1 Andelyn Biosciences Details
9.9.2 Andelyn Biosciences Major Business
9.9.3 Andelyn Biosciences Cell and Gene Therapy CDMO Product and Services
9.9.4 Andelyn Biosciences Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Andelyn Biosciences Recent Developments/Updates
9.9.6 Andelyn Biosciences Competitive Strengths & Weaknesses
9.10 WuXi AppTec
9.10.1 WuXi AppTec Details
9.10.2 WuXi AppTec Major Business
9.10.3 WuXi AppTec Cell and Gene Therapy CDMO Product and Services
9.10.4 WuXi AppTec Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 WuXi AppTec Recent Developments/Updates
9.10.6 WuXi AppTec Competitive Strengths & Weaknesses
9.11 AGC Biologics
9.11.1 AGC Biologics Details
9.11.2 AGC Biologics Major Business
9.11.3 AGC Biologics Cell and Gene Therapy CDMO Product and Services
9.11.4 AGC Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 AGC Biologics Recent Developments/Updates
9.11.6 AGC Biologics Competitive Strengths & Weaknesses
9.12 Pfizer CentreOne
9.12.1 Pfizer CentreOne Details
9.12.2 Pfizer CentreOne Major Business
9.12.3 Pfizer CentreOne Cell and Gene Therapy CDMO Product and Services
9.12.4 Pfizer CentreOne Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Pfizer CentreOne Recent Developments/Updates
9.12.6 Pfizer CentreOne Competitive Strengths & Weaknesses
9.13 Almac Group
9.13.1 Almac Group Details
9.13.2 Almac Group Major Business
9.13.3 Almac Group Cell and Gene Therapy CDMO Product and Services
9.13.4 Almac Group Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Almac Group Recent Developments/Updates
9.13.6 Almac Group Competitive Strengths & Weaknesses
9.14 PCI Pharma Services
9.14.1 PCI Pharma Services Details
9.14.2 PCI Pharma Services Major Business
9.14.3 PCI Pharma Services Cell and Gene Therapy CDMO Product and Services
9.14.4 PCI Pharma Services Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 PCI Pharma Services Recent Developments/Updates
9.14.6 PCI Pharma Services Competitive Strengths & Weaknesses
9.15 OmniaBio
9.15.1 OmniaBio Details
9.15.2 OmniaBio Major Business
9.15.3 OmniaBio Cell and Gene Therapy CDMO Product and Services
9.15.4 OmniaBio Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 OmniaBio Recent Developments/Updates
9.15.6 OmniaBio Competitive Strengths & Weaknesses
9.16 Minaris Advanced Therapies
9.16.1 Minaris Advanced Therapies Details
9.16.2 Minaris Advanced Therapies Major Business
9.16.3 Minaris Advanced Therapies Cell and Gene Therapy CDMO Product and Services
9.16.4 Minaris Advanced Therapies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Minaris Advanced Therapies Recent Developments/Updates
9.16.6 Minaris Advanced Therapies Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Cell and Gene Therapy CDMO Industry Chain
10.2 Cell and Gene Therapy CDMO Upstream Analysis
10.3 Cell and Gene Therapy CDMO Midstream Analysis
10.4 Cell and Gene Therapy CDMO Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Cell and Gene Therapy CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cell and Gene Therapy CDMO Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cell and Gene Therapy CDMO Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cell and Gene Therapy CDMO Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cell and Gene Therapy CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cell and Gene Therapy CDMO Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cell and Gene Therapy CDMO Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cell and Gene Therapy CDMO Players in 2025
Table 12. World Cell and Gene Therapy CDMO Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cell and Gene Therapy CDMO Company Evaluation Quadrant
Table 14. Head Office of Key Cell and Gene Therapy CDMO Players
Table 15. Cell and Gene Therapy CDMO Market: Company Product Type Footprint
Table 16. Cell and Gene Therapy CDMO Market: Company Product Application Footprint
Table 17. Cell and Gene Therapy CDMO Mergers & Acquisitions Activity
Table 18. United States VS China Cell and Gene Therapy CDMO Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cell and Gene Therapy CDMO Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cell and Gene Therapy CDMO Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 23. China Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cell and Gene Therapy CDMO Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 29. World Cell and Gene Therapy CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cell and Gene Therapy CDMO Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cell and Gene Therapy CDMO Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cell and Gene Therapy CDMO Market Size by Scale, (USD Million), 2021 & 2025 & 2032
Table 33. World Cell and Gene Therapy CDMO Market Size Value by Scale (2021-2026) & (USD Million)
Table 34. World Cell and Gene Therapy CDMO Market Size by Scale (2027-2032) & (USD Million)
Table 35. World Cell and Gene Therapy CDMO Market Size by Technology, (USD Million), 2021 & 2025 & 2032
Table 36. World Cell and Gene Therapy CDMO Market Size Value by Technology (2021-2026) & (USD Million)
Table 37. World Cell and Gene Therapy CDMO Market Size by Technology (2027-2032) & (USD Million)
Table 38. World Cell and Gene Therapy CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cell and Gene Therapy CDMO Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cell and Gene Therapy CDMO Market Size by Application (2027-2032) & (USD Million)
Table 41. Lonza Basic Information, Manufacturing Base and Competitors
Table 42. Lonza Major Business
Table 43. Lonza Cell and Gene Therapy CDMO Product and Services
Table 44. Lonza Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Lonza Recent Developments/Updates
Table 46. Lonza Competitive Strengths & Weaknesses
Table 47. Charles River Laboratories Basic Information, Manufacturing Base and Competitors
Table 48. Charles River Laboratories Major Business
Table 49. Charles River Laboratories Cell and Gene Therapy CDMO Product and Services
Table 50. Charles River Laboratories Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Charles River Laboratories Recent Developments/Updates
Table 52. Charles River Laboratories Competitive Strengths & Weaknesses
Table 53. Cytiva Basic Information, Manufacturing Base and Competitors
Table 54. Cytiva Major Business
Table 55. Cytiva Cell and Gene Therapy CDMO Product and Services
Table 56. Cytiva Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Cytiva Recent Developments/Updates
Table 58. Cytiva Competitive Strengths & Weaknesses
Table 59. Catalent Biologics Basic Information, Manufacturing Base and Competitors
Table 60. Catalent Biologics Major Business
Table 61. Catalent Biologics Cell and Gene Therapy CDMO Product and Services
Table 62. Catalent Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Catalent Biologics Recent Developments/Updates
Table 64. Catalent Biologics Competitive Strengths & Weaknesses
Table 65. FUJIFILM Diosynth Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 66. FUJIFILM Diosynth Biotechnologies Major Business
Table 67. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product and Services
Table 68. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
Table 70. FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
Table 71. Made Scientific Basic Information, Manufacturing Base and Competitors
Table 72. Made Scientific Major Business
Table 73. Made Scientific Cell and Gene Therapy CDMO Product and Services
Table 74. Made Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Made Scientific Recent Developments/Updates
Table 76. Made Scientific Competitive Strengths & Weaknesses
Table 77. RoslinCT Basic Information, Manufacturing Base and Competitors
Table 78. RoslinCT Major Business
Table 79. RoslinCT Cell and Gene Therapy CDMO Product and Services
Table 80. RoslinCT Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. RoslinCT Recent Developments/Updates
Table 82. RoslinCT Competitive Strengths & Weaknesses
Table 83. Thermo Scientific Basic Information, Manufacturing Base and Competitors
Table 84. Thermo Scientific Major Business
Table 85. Thermo Scientific Cell and Gene Therapy CDMO Product and Services
Table 86. Thermo Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Thermo Scientific Recent Developments/Updates
Table 88. Thermo Scientific Competitive Strengths & Weaknesses
Table 89. Andelyn Biosciences Basic Information, Manufacturing Base and Competitors
Table 90. Andelyn Biosciences Major Business
Table 91. Andelyn Biosciences Cell and Gene Therapy CDMO Product and Services
Table 92. Andelyn Biosciences Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Andelyn Biosciences Recent Developments/Updates
Table 94. Andelyn Biosciences Competitive Strengths & Weaknesses
Table 95. WuXi AppTec Basic Information, Manufacturing Base and Competitors
Table 96. WuXi AppTec Major Business
Table 97. WuXi AppTec Cell and Gene Therapy CDMO Product and Services
Table 98. WuXi AppTec Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. WuXi AppTec Recent Developments/Updates
Table 100. WuXi AppTec Competitive Strengths & Weaknesses
Table 101. AGC Biologics Basic Information, Manufacturing Base and Competitors
Table 102. AGC Biologics Major Business
Table 103. AGC Biologics Cell and Gene Therapy CDMO Product and Services
Table 104. AGC Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. AGC Biologics Recent Developments/Updates
Table 106. AGC Biologics Competitive Strengths & Weaknesses
Table 107. Pfizer CentreOne Basic Information, Manufacturing Base and Competitors
Table 108. Pfizer CentreOne Major Business
Table 109. Pfizer CentreOne Cell and Gene Therapy CDMO Product and Services
Table 110. Pfizer CentreOne Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Pfizer CentreOne Recent Developments/Updates
Table 112. Pfizer CentreOne Competitive Strengths & Weaknesses
Table 113. Almac Group Basic Information, Manufacturing Base and Competitors
Table 114. Almac Group Major Business
Table 115. Almac Group Cell and Gene Therapy CDMO Product and Services
Table 116. Almac Group Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Almac Group Recent Developments/Updates
Table 118. Almac Group Competitive Strengths & Weaknesses
Table 119. PCI Pharma Services Basic Information, Manufacturing Base and Competitors
Table 120. PCI Pharma Services Major Business
Table 121. PCI Pharma Services Cell and Gene Therapy CDMO Product and Services
Table 122. PCI Pharma Services Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. PCI Pharma Services Recent Developments/Updates
Table 124. PCI Pharma Services Competitive Strengths & Weaknesses
Table 125. OmniaBio Basic Information, Manufacturing Base and Competitors
Table 126. OmniaBio Major Business
Table 127. OmniaBio Cell and Gene Therapy CDMO Product and Services
Table 128. OmniaBio Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. OmniaBio Recent Developments/Updates
Table 130. OmniaBio Competitive Strengths & Weaknesses
Table 131. Minaris Advanced Therapies Basic Information, Manufacturing Base and Competitors
Table 132. Minaris Advanced Therapies Major Business
Table 133. Minaris Advanced Therapies Cell and Gene Therapy CDMO Product and Services
Table 134. Minaris Advanced Therapies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Minaris Advanced Therapies Recent Developments/Updates
Table 136. Minaris Advanced Therapies Competitive Strengths & Weaknesses
Table 137. Global Key Players of Cell and Gene Therapy CDMO Upstream (Raw Materials)
Table 138. Global Cell and Gene Therapy CDMO Typical Customers
Table 1. World Cell and Gene Therapy CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Cell and Gene Therapy CDMO Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Cell and Gene Therapy CDMO Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Cell and Gene Therapy CDMO Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Cell and Gene Therapy CDMO Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Cell and Gene Therapy CDMO Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Cell and Gene Therapy CDMO Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Cell and Gene Therapy CDMO Players in 2025
Table 12. World Cell and Gene Therapy CDMO Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Cell and Gene Therapy CDMO Company Evaluation Quadrant
Table 14. Head Office of Key Cell and Gene Therapy CDMO Players
Table 15. Cell and Gene Therapy CDMO Market: Company Product Type Footprint
Table 16. Cell and Gene Therapy CDMO Market: Company Product Application Footprint
Table 17. Cell and Gene Therapy CDMO Mergers & Acquisitions Activity
Table 18. United States VS China Cell and Gene Therapy CDMO Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Cell and Gene Therapy CDMO Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Cell and Gene Therapy CDMO Companies, Headquarters (States, Country)
Table 21. United States Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 23. China Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
Table 24. China Based Companies Cell and Gene Therapy CDMO Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 26. Rest of World Based Cell and Gene Therapy CDMO Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Cell and Gene Therapy CDMO Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Cell and Gene Therapy CDMO Revenue Market Share (2021-2026)
Table 29. World Cell and Gene Therapy CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Cell and Gene Therapy CDMO Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Cell and Gene Therapy CDMO Market Size by Type (2027-2032) & (USD Million)
Table 32. World Cell and Gene Therapy CDMO Market Size by Scale, (USD Million), 2021 & 2025 & 2032
Table 33. World Cell and Gene Therapy CDMO Market Size Value by Scale (2021-2026) & (USD Million)
Table 34. World Cell and Gene Therapy CDMO Market Size by Scale (2027-2032) & (USD Million)
Table 35. World Cell and Gene Therapy CDMO Market Size by Technology, (USD Million), 2021 & 2025 & 2032
Table 36. World Cell and Gene Therapy CDMO Market Size Value by Technology (2021-2026) & (USD Million)
Table 37. World Cell and Gene Therapy CDMO Market Size by Technology (2027-2032) & (USD Million)
Table 38. World Cell and Gene Therapy CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Cell and Gene Therapy CDMO Market Size by Application (2021-2026) & (USD Million)
Table 40. World Cell and Gene Therapy CDMO Market Size by Application (2027-2032) & (USD Million)
Table 41. Lonza Basic Information, Manufacturing Base and Competitors
Table 42. Lonza Major Business
Table 43. Lonza Cell and Gene Therapy CDMO Product and Services
Table 44. Lonza Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Lonza Recent Developments/Updates
Table 46. Lonza Competitive Strengths & Weaknesses
Table 47. Charles River Laboratories Basic Information, Manufacturing Base and Competitors
Table 48. Charles River Laboratories Major Business
Table 49. Charles River Laboratories Cell and Gene Therapy CDMO Product and Services
Table 50. Charles River Laboratories Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Charles River Laboratories Recent Developments/Updates
Table 52. Charles River Laboratories Competitive Strengths & Weaknesses
Table 53. Cytiva Basic Information, Manufacturing Base and Competitors
Table 54. Cytiva Major Business
Table 55. Cytiva Cell and Gene Therapy CDMO Product and Services
Table 56. Cytiva Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Cytiva Recent Developments/Updates
Table 58. Cytiva Competitive Strengths & Weaknesses
Table 59. Catalent Biologics Basic Information, Manufacturing Base and Competitors
Table 60. Catalent Biologics Major Business
Table 61. Catalent Biologics Cell and Gene Therapy CDMO Product and Services
Table 62. Catalent Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Catalent Biologics Recent Developments/Updates
Table 64. Catalent Biologics Competitive Strengths & Weaknesses
Table 65. FUJIFILM Diosynth Biotechnologies Basic Information, Manufacturing Base and Competitors
Table 66. FUJIFILM Diosynth Biotechnologies Major Business
Table 67. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product and Services
Table 68. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. FUJIFILM Diosynth Biotechnologies Recent Developments/Updates
Table 70. FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses
Table 71. Made Scientific Basic Information, Manufacturing Base and Competitors
Table 72. Made Scientific Major Business
Table 73. Made Scientific Cell and Gene Therapy CDMO Product and Services
Table 74. Made Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Made Scientific Recent Developments/Updates
Table 76. Made Scientific Competitive Strengths & Weaknesses
Table 77. RoslinCT Basic Information, Manufacturing Base and Competitors
Table 78. RoslinCT Major Business
Table 79. RoslinCT Cell and Gene Therapy CDMO Product and Services
Table 80. RoslinCT Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. RoslinCT Recent Developments/Updates
Table 82. RoslinCT Competitive Strengths & Weaknesses
Table 83. Thermo Scientific Basic Information, Manufacturing Base and Competitors
Table 84. Thermo Scientific Major Business
Table 85. Thermo Scientific Cell and Gene Therapy CDMO Product and Services
Table 86. Thermo Scientific Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Thermo Scientific Recent Developments/Updates
Table 88. Thermo Scientific Competitive Strengths & Weaknesses
Table 89. Andelyn Biosciences Basic Information, Manufacturing Base and Competitors
Table 90. Andelyn Biosciences Major Business
Table 91. Andelyn Biosciences Cell and Gene Therapy CDMO Product and Services
Table 92. Andelyn Biosciences Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Andelyn Biosciences Recent Developments/Updates
Table 94. Andelyn Biosciences Competitive Strengths & Weaknesses
Table 95. WuXi AppTec Basic Information, Manufacturing Base and Competitors
Table 96. WuXi AppTec Major Business
Table 97. WuXi AppTec Cell and Gene Therapy CDMO Product and Services
Table 98. WuXi AppTec Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. WuXi AppTec Recent Developments/Updates
Table 100. WuXi AppTec Competitive Strengths & Weaknesses
Table 101. AGC Biologics Basic Information, Manufacturing Base and Competitors
Table 102. AGC Biologics Major Business
Table 103. AGC Biologics Cell and Gene Therapy CDMO Product and Services
Table 104. AGC Biologics Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. AGC Biologics Recent Developments/Updates
Table 106. AGC Biologics Competitive Strengths & Weaknesses
Table 107. Pfizer CentreOne Basic Information, Manufacturing Base and Competitors
Table 108. Pfizer CentreOne Major Business
Table 109. Pfizer CentreOne Cell and Gene Therapy CDMO Product and Services
Table 110. Pfizer CentreOne Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Pfizer CentreOne Recent Developments/Updates
Table 112. Pfizer CentreOne Competitive Strengths & Weaknesses
Table 113. Almac Group Basic Information, Manufacturing Base and Competitors
Table 114. Almac Group Major Business
Table 115. Almac Group Cell and Gene Therapy CDMO Product and Services
Table 116. Almac Group Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Almac Group Recent Developments/Updates
Table 118. Almac Group Competitive Strengths & Weaknesses
Table 119. PCI Pharma Services Basic Information, Manufacturing Base and Competitors
Table 120. PCI Pharma Services Major Business
Table 121. PCI Pharma Services Cell and Gene Therapy CDMO Product and Services
Table 122. PCI Pharma Services Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. PCI Pharma Services Recent Developments/Updates
Table 124. PCI Pharma Services Competitive Strengths & Weaknesses
Table 125. OmniaBio Basic Information, Manufacturing Base and Competitors
Table 126. OmniaBio Major Business
Table 127. OmniaBio Cell and Gene Therapy CDMO Product and Services
Table 128. OmniaBio Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. OmniaBio Recent Developments/Updates
Table 130. OmniaBio Competitive Strengths & Weaknesses
Table 131. Minaris Advanced Therapies Basic Information, Manufacturing Base and Competitors
Table 132. Minaris Advanced Therapies Major Business
Table 133. Minaris Advanced Therapies Cell and Gene Therapy CDMO Product and Services
Table 134. Minaris Advanced Therapies Cell and Gene Therapy CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Minaris Advanced Therapies Recent Developments/Updates
Table 136. Minaris Advanced Therapies Competitive Strengths & Weaknesses
Table 137. Global Key Players of Cell and Gene Therapy CDMO Upstream (Raw Materials)
Table 138. Global Cell and Gene Therapy CDMO Typical Customers
LIST OF FIGURES
Figure 1. Cell and Gene Therapy CDMO Picture
Figure 2. World Cell and Gene Therapy CDMO Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cell and Gene Therapy CDMO Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cell and Gene Therapy CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 13. Cell and Gene Therapy CDMO Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cell and Gene Therapy CDMO Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cell and Gene Therapy CDMO by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cell and Gene Therapy CDMO Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cell and Gene Therapy CDMO Markets in 2025
Figure 27. United States VS China: Cell and Gene Therapy CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cell and Gene Therapy CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cell and Gene Therapy CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cell and Gene Therapy CDMO Market Size Market Share by Type in 2025
Figure 31. Clinical Trial Material CDMOs
Figure 32. Development and Manufacturing CDMOs
Figure 33. Other
Figure 34. World Cell and Gene Therapy CDMO Market Size Market Share by Type (2021-2032)
Figure 35. World Cell and Gene Therapy CDMO Market Size by Scale, (USD Million), 2021 & 2025 & 2032
Figure 36. World Cell and Gene Therapy CDMO Market Size Market Share by Scale in 2025
Figure 37. R&D-Grade CDMO
Figure 38. Clinical-Grade CDMO
Figure 39. Commercial-Scale CDMO
Figure 40. World Cell and Gene Therapy CDMO Market Size Market Share by Scale (2021-2032)
Figure 41. World Cell and Gene Therapy CDMO Market Size by Technology, (USD Million), 2021 & 2025 & 2032
Figure 42. World Cell and Gene Therapy CDMO Market Size Market Share by Technology in 2025
Figure 43. Plasmid DNA CDMO
Figure 44. Viral Vector CDMO
Figure 45. Cell Therapy CDMO
Figure 46. mRNA Drug CDMO
Figure 47. Gene Editing Drug CDMO
Figure 48. Others
Figure 49. World Cell and Gene Therapy CDMO Market Size Market Share by Technology (2021-2032)
Figure 50. World Cell and Gene Therapy CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Cell and Gene Therapy CDMO Market Size Market Share by Application in 2025
Figure 52. Pharmaceutical Company
Figure 53. Biotechnology Company
Figure 54. Other
Figure 55. World Cell and Gene Therapy CDMO Market Size Market Share by Application (2021-2032)
Figure 56. Cell and Gene Therapy CDMO Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
Figure 1. Cell and Gene Therapy CDMO Picture
Figure 2. World Cell and Gene Therapy CDMO Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cell and Gene Therapy CDMO Total Revenue (2021-2032) & (USD Million)
Figure 4. World Cell and Gene Therapy CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Cell and Gene Therapy CDMO Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Cell and Gene Therapy CDMO Revenue (2021-2032) & (USD Million)
Figure 13. Cell and Gene Therapy CDMO Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 16. World Cell and Gene Therapy CDMO Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 18. China Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 23. India Cell and Gene Therapy CDMO Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Cell and Gene Therapy CDMO by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Cell and Gene Therapy CDMO Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Cell and Gene Therapy CDMO Markets in 2025
Figure 27. United States VS China: Cell and Gene Therapy CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cell and Gene Therapy CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Cell and Gene Therapy CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Cell and Gene Therapy CDMO Market Size Market Share by Type in 2025
Figure 31. Clinical Trial Material CDMOs
Figure 32. Development and Manufacturing CDMOs
Figure 33. Other
Figure 34. World Cell and Gene Therapy CDMO Market Size Market Share by Type (2021-2032)
Figure 35. World Cell and Gene Therapy CDMO Market Size by Scale, (USD Million), 2021 & 2025 & 2032
Figure 36. World Cell and Gene Therapy CDMO Market Size Market Share by Scale in 2025
Figure 37. R&D-Grade CDMO
Figure 38. Clinical-Grade CDMO
Figure 39. Commercial-Scale CDMO
Figure 40. World Cell and Gene Therapy CDMO Market Size Market Share by Scale (2021-2032)
Figure 41. World Cell and Gene Therapy CDMO Market Size by Technology, (USD Million), 2021 & 2025 & 2032
Figure 42. World Cell and Gene Therapy CDMO Market Size Market Share by Technology in 2025
Figure 43. Plasmid DNA CDMO
Figure 44. Viral Vector CDMO
Figure 45. Cell Therapy CDMO
Figure 46. mRNA Drug CDMO
Figure 47. Gene Editing Drug CDMO
Figure 48. Others
Figure 49. World Cell and Gene Therapy CDMO Market Size Market Share by Technology (2021-2032)
Figure 50. World Cell and Gene Therapy CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Cell and Gene Therapy CDMO Market Size Market Share by Application in 2025
Figure 52. Pharmaceutical Company
Figure 53. Biotechnology Company
Figure 54. Other
Figure 55. World Cell and Gene Therapy CDMO Market Size Market Share by Application (2021-2032)
Figure 56. Cell and Gene Therapy CDMO Industrial Chain
Figure 57. Methodology
Figure 58. Research Process and Data Source
